RedHill Biopharma receives Nasdaq extension to regain compliance by October

Published 14/08/2025, 12:14
© Redhill Biopharma PR

RedHill Biopharma Ltd. (NASDAQ:RDHL) announced Thursday that it has been granted an extension by the Nasdaq Stock Market LLC to regain compliance with Nasdaq Listing Rule 5550(b), which requires listed companies to maintain a minimum stockholders’ equity of $2.5 million.

According to a statement based on a recent SEC filing, Nasdaq’s Listing Qualifications Department issued an extension letter on August 8, allowing RedHill Biopharma until October 13, 2025, to meet the equity requirement for continued listing on the exchange.

The company previously reported that it received a deficiency notice from Nasdaq on April 15, 2025, for failing to comply with the minimum stockholders’ equity rule. RedHill Biopharma submitted a plan to Nasdaq outlining steps to regain compliance, which led to the current extension.

If the company does not meet the compliance requirement by October 13, it may appeal any determination of non-compliance to a Nasdaq Hearings Panel. An accepted appeal could provide RedHill Biopharma with additional time to regain compliance.

This information is based on a press release statement included in the company’s recent SEC filing.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.